219 related articles for article (PubMed ID: 12379721)
1. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.
Cheng Q; Debol S; Lam H; Eby R; Edwards L; Matsuka Y; Olmsted SB; Cleary PP
Infect Immun; 2002 Nov; 70(11):6409-15. PubMed ID: 12379721
[TBL] [Abstract][Full Text] [Related]
2. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.
Cheng Q; Carlson B; Pillai S; Eby R; Edwards L; Olmsted SB; Cleary P
Infect Immun; 2001 Apr; 69(4):2302-8. PubMed ID: 11254587
[TBL] [Abstract][Full Text] [Related]
3. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
4. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
[TBL] [Abstract][Full Text] [Related]
5. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
6. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
[TBL] [Abstract][Full Text] [Related]
7. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
8. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
[TBL] [Abstract][Full Text] [Related]
9. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; LagergÄrd T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
10. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
Madoff LC; Paoletti LC; Tai JY; Kasper DL
J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
[TBL] [Abstract][Full Text] [Related]
11. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase.
Santillan DA; Andracki ME; Hunter SK
Am J Obstet Gynecol; 2008 Jan; 198(1):114.e1-6. PubMed ID: 17905172
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
13. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
15. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model.
Santillan DA; Rai KK; Santillan MK; Krishnamachari Y; Salem AK; Hunter SK
Am J Obstet Gynecol; 2011 Sep; 205(3):249.e1-8. PubMed ID: 21802065
[TBL] [Abstract][Full Text] [Related]
17. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
[TBL] [Abstract][Full Text] [Related]
18. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.
Edwards MS; Lane HJ; Hillier SL; Rench MA; Baker CJ
Vaccine; 2012 Jun; 30(28):4123-6. PubMed ID: 22537994
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
20. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]